Literature DB >> 1746428

Initial blood pressure response to enalapril in hospitalized patients (Studies of Left Ventricular Dysfunction [SOLVD]).

W B Hood1, M Youngblood, J K Ghali, M Reid, W J Rogers, D Howe, K K Teo, T H LeJemtel.   

Abstract

Studies of Left Ventricular Dysfunction (SOLVD) is a randomized trial of enalapril versus placebo in reducing mortality in patients with cardiac dysfunction (defined as left ventricular ejection fraction less than or equal to 35%). Before randomization, patients at risk for hypotension were hospitalized for a test dose of 2.5 mg of enalapril administered orally at baseline and again 12 hours later. As of February 1989, 89 of 7,539 (1.2%) patients had been studied during hospitalization. Baseline systolic and diastolic blood pressures were 115 +/- 18 and 73 +/- 10 mm Hg, respectively. After enalapril, systolic blood pressure decreased slightly but significantly 8 to 20 hours after the initial dose (mean reduction 8 to 11 mm Hg). In this highly selected group of 89 patients, symptoms relating to decrease in blood pressure were noted in 13 (15%). It is emphasized that most patients with cardiac dysfunction readily tolerate enalapril. However, the agent should be administered with caution to patients with advanced congestive failure and diminished baseline blood pressure, owing to a significant incidence of symptomatic hypotension.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1746428     DOI: 10.1016/0002-9149(91)90280-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  2 in total

Review 1.  ACE inhibitors. Differential use in elderly patients with hypertension.

Authors:  Z H Israili; W D Hall
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

2.  Changes in heart failure medications in patients hospitalised and discharged.

Authors:  Martin Scherer; Cordula Sobek; Dirk Wetzel; Janka Koschack; Michael M Kochen
Journal:  BMC Fam Pract       Date:  2006-11-23       Impact factor: 2.497

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.